New Possibilities: Medicinal Cannabis in Diabetes Management
With over 1 in 20 or just over 1.3 million Australians currently living with diabetes, exploring alternative therapies is crucial in the fight for better treatment management. Medicinal cannabis offers a promising, yet still developing, approach as an adjunct to conventional treatments.
Left unchecked, diabetes can wreak havoc on the body. High blood sugar damages blood vessels, raising the risk of heart attack and stroke. Kidneys become less efficient, potentially leading to failure. Diabetic retinopathy threatens vision, while nerve damage causes pain, numbness, and even impacts digestion and sexual function. Additionally, poor circulation and nerve damage in the feet increase the risk of ulcers and infections, sometimes requiring amputation.1
Emerging research suggests that cannabis compounds, particularly cannabinoids like CBD and THC, may hold therapeutic potential for diabetes management. Studies indicate that cannabinoids possess anti-inflammatory properties, potentially mitigating the chronic inflammation associated with diabetes and its complications.2
Moreover, cannabis has shown promise in addressing key facets of diabetes management, including:
- Blood Glucose Regulation: Certain cannabinoids exhibit glucose-lowering effects, aiding in the regulation of blood sugar levels, a cornerstone of diabetes management.3
- Neuropathy Relief: Diabetic neuropathy, characterised by nerve damage and pain, is a common complication. Cannabis-derived compounds may alleviate neuropathic pain, enhancing patients' quality of life.4
- Insulin Sensitivity: Research suggests that cannabinoids may enhance insulin sensitivity, potentially offering therapeutic benefits for individuals with insulin resistance or type 2 diabetes.5
Approaching the integration of medicinal cannabis into diabetes treatment plans demands careful consideration and expertise. It's essential for healthcare providers to educate patients on the potential risks associated with cannabis, such as interactions with existing medications and the psychotropic effects of THC. While cannabis shouldn't be viewed as a standalone treatment, it holds promise as a potential adjunct therapy.
- Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-1264. doi:10.2522/ptj.20080020
- Horváth B, Mukhopadhyay P, Haskó G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180(2):432-442. doi:10.1016/j.ajpath.2011.11.003
- IBID
- Bennici A, Mannucci C, Calapai F, et al. Safety of medical cannabis in neuropathic chronic pain management. Molecules. 2021 Oct;26(20):6257. doi:10.3390/molecules26206257
- Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Ame J Med. 2013;126(7):583-589. doi:10.1016/j.amjmed.2013.03.002